Catherine Owen Adams, Chief Executive Officer at Acadia Pharmaceuticals Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Catherine Owen Adams has served as ACADIA's Chief Executive Officer and as a member of the Board of Directors since September 2024, succeeding Stephen R. Davis. She brings more than 25 years of biopharmaceutical leadership. Previously she was Senior Vice President and General Manager, U.S. at Bristol Myers Squibb (2019-2024), where she led a $20 billion commercial business across Oncology, Cardiovascular and Immunology, and earlier served as Senior Vice President, Head of Major Markets at BMS during its merger with Celgene. Before BMS she spent 25 years at Johnson & Johnson, culminating as President, Janssen Immunology U.S. She currently serves on the boards of Agios Pharmaceuticals and AssistRx, and earned a BSc in Pharmacy from the University of Manchester.
Roles
Acadia Pharmaceuticals Inc.
Chief Executive Officer · Current role
September 2024–present
ACADIA Pharmaceuticals
Chief Executive Officer and Director
September 2024 - present
Bristol Myers Squibb
Senior Vice President and General Manager, U.S.
September 2019 - April 2024
Bristol Myers Squibb
Senior Vice President, Head of Major Markets
2019 - 2019
Johnson & Johnson
President, Janssen Immunology U.S. (last role in 25-year tenure)
1994 - 2019
AstraZeneca
R&D and manufacturing roles (early career)
—
External Roles
Agios Pharmaceuticals, Inc.
Director
—
AssistRx
Director
—
Optinose PLC
Director and Compensation Committee Chair
former
Fixed Compensation
FY 2025
Salary
$930,000
ComponentAnnual base salary earned in FY2025
All other compensation
$32,604
Component401(k) match, insurance premiums, and other perquisites
Total compensation
$8,256,518
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$818,559
Target Opportunity
—
PlanAnnual cash bonus under the corporate incentive plan